Cambridge Cognition - World Leading Cognitive Assessment Tools
492 FOLLOWERS
Cambridge Cognition is a neuroscience digital health company developing products and services to better understand, detect and treat conditions affecting the brain.
Cambridge Cognition - World Leading Cognitive Assessment Tools
1w ago
News
Cambridge Cognition announces scientific advisory board
Cambridge, UK – 21 March 2024: Cambridge Cognition, a leader in digital health solutions for brain health assessment, announces the formation of a Scientific Advisory Board (SAB). This expert board will provide scientific guidance and valuable market insights, primarily focusing on addressing emerging trends such as the integration of blood-based biomarkers and the collaborative possibilities for computerised cognitive assessments.
The SAB combines expertise covering CNS-related disorders, clinical development, and academia w ..read more
Cambridge Cognition - World Leading Cognitive Assessment Tools
3w ago
eBooks & Whitepapers, Publications & posters
Digital measures to advance research & quality of life in schizophrenia
Schizophrenia spectrum disorders are complex and serious psychiatric disorders. In addition to prominent psychiatric symptoms such as hallucinations, delusions, and negative symptoms (e.g., loss of motivation), schizophrenia is associated with functional impairment in major life areas (e.g., occupational and interpersonal functioning).
This functional impairment has been linked not only to the psychiatric symptoms noted above, but also to associated deficits i ..read more
Cambridge Cognition - World Leading Cognitive Assessment Tools
1M ago
News
Back to resource centre
20 September 2023
Cambridge Cognition's Global Teams Unite for Mental Health Causes!
Last weekend marked the annual charity challenge here at Cambridge cognition, teams from the UK and Canada came together for two challenging fundraising events. Our UK team conquered the 47-mile Norfolk Coastal Path in less than 24 hours, raising funds for Sport in Mind, while our Canadian team completed a 12 km walk/run for the Alzheimer Society of Toronto.
Engaging in charity challenges provides us with the opportunity to both personally and directly make a diffe ..read more
Cambridge Cognition - World Leading Cognitive Assessment Tools
3M ago
Insights,
Technology for successful decentralised clinical trials
The landscape of clinical trials is undergoing a profound transformation, one that holds the promise of faster drug development, increased patient participation, and improved data quality.
At the forefront of this revolution stands the concept of Decentralised Clinical Trials (DCTs), a game-changing approach that is reshaping the way we conduct clinical research. In this blog post, we’ll delve into the world of DCTs, exploring their benefits, challenges, and the role of technology in driving this paradigm shift ..read more
Cambridge Cognition - World Leading Cognitive Assessment Tools
5M ago
Success Factors for Remote and Hybrid Decentralised Trials From Site, Technology and Service Provider Perspectives with a Focus on the RADIAL Study from Trials@Home
About this webinar
Thursday 16th November 2023
15:00-16:00 BST | 10:00-11:00 EST
Platform: Zoom Webinars
Amidst the enthusiasm surrounding the advantages and efficiencies promised by Decentralised Clinical Trials (DCTs), encompassing remote or hybrid trials, an imperative gap remains – the need for deeper understanding, agreement, and standardization of optimal practices and protocol.
When executed thoughtfully, accounting ..read more
Cambridge Cognition - World Leading Cognitive Assessment Tools
6M ago
News
Back to resource centre
4 October 2023
2023 CANTAB Research Grant winners announced
It has been another highly competitive year for our CANTABTM Research Grant, with the large number of high-quality applications making picking just three winners a challenge for our judging panel! Here we reveal the winning grants.
The winners each receive a CANTABTM Connect Research Licence with 150 CANTABTM assessments alongside funding to support the costs of the study and access to expert support from our science team.
We are pleased to announce the winners of the 2022 CANTABTM Research ..read more
Cambridge Cognition - World Leading Cognitive Assessment Tools
6M ago
News
Back to resource centre
20 September 2023
Cambridge Cognition's Global Teams Unite for Mental Health Causes!
Last weekend marked the annual charity challenge here at Cambridge cognition, teams from the UK and Canada came together for two challenging fundraising events. Our UK team conquered the 47-mile Norfolk Coastal Path in less than 24 hours, raising funds for Sport in Mind, while our Canadian team completed a 12 km walk/run for the Alzheimer Society of Toronto.
Engaging in charity challenges provides us with the opportunity to both personally and directly make a diffe ..read more
Cambridge Cognition - World Leading Cognitive Assessment Tools
7M ago
Insights
Back to resource centre
30 August 2023
Speech based biomarkers for monitoring progressive changes in Alzheimer’s disease
A speech based composite which tracks change in AD over time was recently developed and piloted through a collaboration between Winterlight Labs and Genentech.
Speech is a rich source of clinical information when assessing and monitoring Alzheimer’s Disease. Natural language processing technologies, like those developed by Winterlight Labs, can objectively quantify speech and enable its use as a novel endpoint in drug development.
Using speech from clini ..read more
Cambridge Cognition - World Leading Cognitive Assessment Tools
7M ago
Insights
Back to resource centre
17 August 2023
The next generation of treatments for Alzheimer’s Disease in clinical trials
The latest advances in the treatment of Alzheimer's disease and how Cambridge Cognition are designing and implementing empirically validated and clinically-relevant cognitive tasks to help develop the next generation of Alzheimer’s disease treatments.
There are presently over 140 drugs being explored as possible treatments for Alzheimer’s Disease (AD) in clinical trials. Of these, nearly 80% are intended to slow the progression of AD. Historically, cholinest ..read more
Cambridge Cognition - World Leading Cognitive Assessment Tools
8M ago
Insights
Highlights from AAIC 2023
August 7, 2023
Donanemab trial results
The headline from this year’s AAIC in Amsterdam is undoubtedly the announcement of the results of TRAILBLAZER-ALZ-2, a phase 3 trial of Eli Lilly’s new drug Donanemab with 1,800 participants. Donanemab is an antibody-based drug that works by breaking down already-formed amyloid plaques that build up in Alzheimer’s disease (AD), rather than interfering with their production.
The results presented from this trial are promising as they showed significant slowing in cognitive and functional decline associated wi ..read more